Island Pharmaceuticals Limited (ASX:ILA)

Australia flag Australia · Delayed Price · Currency is AUD
0.4900
+0.0050 (1.03%)
At close: Mar 11, 2026
Market Cap142.96M +458.5%
Revenue (ttm)62.85K -84.3%
Net Income-7.20M
EPS-0.03
Shares Out294.77M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume381,527
Average Volume444,090
Open0.4900
Previous Close0.4850
Day's Range0.4800 - 0.5150
52-Week Range0.1200 - 0.6300
Beta0.13
RSI71.95
Earnings DateFeb 22, 2026

About Island Pharmaceuticals

Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol ILA
Full Company Profile

Financial Performance

In fiscal year 2025, Island Pharmaceuticals's revenue was 118,910, a decrease of -90.57% compared to the previous year's 1.26 million. Losses were -3.92 million, 36.9% more than in 2024.

Financial Statements